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Abstract
CD8+ T cell immunosurveillance is crucial in solid tumors and T cell dysfunction leads to tumor progression. In contrast, the role
of CD8+ T cells in the control of leukemia is less clear. We characterized the molecular signature of leukemia stem/progenitor
cells (LSPCs) and paired CD8+ T cells in patients with acute myeloid leukemia (AML). Epigenetic alterations via histone
deacetylation reduced the expression of immune-related genes in bone marrow (BM)-inﬁltrating CD8+ T cells. Surprisingly, a
silenced gene expression pattern in CD8+ T cells signiﬁcantly correlated with an improved prognosis. To deﬁne interactions
between CD8+ T cells and LSPCs, we performed comprehensive correlative network modeling. This analysis indicated that
CD8+ T cells contribute to the maintenance/expansion of LSPCs, particularly in favorable risk AML. Functionally, CD8+ T cells
in favorable AML induced the expansion of LSPCs by stimulating the autocrine production of important hematopoietic cytokines
such as interleukin (IL)-3. In contrast, LSPCs in aggressive AML were characterized by a higher activation of stemness/
proliferation-related pathways and develop independent of BM CD8+ T cells. Overall, our study indicates that CD8+ T cells
support and expand LSPCs in favorable risk AML whereas intermediate and adverse risk AML possess the intrinsic molecular
abnormalities to develop independently.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous group
of hematologic malignant diseases, characterized by
maturation arrest and increased proliferation of myeloid
blasts [1, 2]. Based on the (cyto)genetic proﬁle of AML
blasts, patients can be classiﬁed into three different
risk groups: favorable risk (40–45%), intermediate risk
(25–35%), and adverse risk (25–30%) [3].
Leukemia stem cells (LSCs) represent a minor fraction of
the bulk leukemia cell population that reconstitutes and
propagates the disease. They are resistant to chemotherapy
and irradiation and therefore are the main cause of relapse
[4–8]. LSCs possess stem cell properties such as self-
renewal and quiescence that are regulated by cell-intrinsic
and cell-extrinsic mechanisms [9–11]. As cell-intrinsic
drivers, LSCs display molecular abnormalities that lead to
constitutive activation of the nuclear factor kB (NF-kB) [2],
Wnt [12], and Notch signaling pathways [13]. In addition,
similar to hematopoietic stem cells (HSCs), LSCs interact
with cells of the bone marrow (BM) microenvironment,
including endothelial cells, specialized BM stromal cells,
and osteoblasts [14–16]. These cells constitute the HSC
niche and regulate maintenance, self-renewal, and differ-
entiation of HSCs and LSCs [17]. Immune cells are part of
the BM microenvironment and interact with HSCs as
well as leukemia stem and progenitor cells (LSPCs). For
example, CD8+ T cells have the potential to support the
maintenance of HSCs and facilitate their engraftment after
allogeneic stem-cell transplantation [18, 19].
It is well documented that AML responds to immune-
mediated therapies such as allogeneic hematopoietic stem
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cell transplantation and donor lymphocyte infusions
[14, 20]. Similarly, AML blasts can be lysed by
adoptively transferred gene-modiﬁed T cells in xeno-
transplantation experiments [21]. However, several
studies indicate that LSCs escape elimination by CD8+
T cell and natural killer (NK) cells by down-regulating
important molecules/pathways for immune recognition
or by the expression of immune-inhibitory molecules
[22, 23]. Experimental evidence indicates that cytokines
secreted by immune cells and deﬁned cell–cell interac-
tions such as the CD70/CD27 interaction expand HSCs
and LSCs and contribute to disease progression [24, 25].
However, the role of the adaptive immune system in the
control of human AML and especially in the regulation of
LSCs is poorly understood.
We performed a comprehensive transcriptomic proﬁl-
ing of BM-derived LSCs and leukemia progenitor
cells together with paired CD8+ T cells of AML patients
from different molecular risk groups. This analysis
indicated that epigenetic mechanisms silence the
gene expression of CD8+ T cells in AML. Importantly,
a silenced gene expression pattern correlated with
improved prognosis. Correlation network modeling
revealed that CD8+ T cells regulate LSPC in favorable
risk but not in adverse risk AML. Functionally, we
show that CD8+ T cells induce the autocrine production
of the hematopoietic cytokines such as IL-3 in favorable
risk AML that expands LSPCs. The interaction of CD8+
T cells with LSPCs was gradually lost from favorable
risk to intermediate and adverse risk AML. In contrast,
LSPCs from patients with intermediate and adverse
risk AML had a higher expression of genes related to
stemness and cell proliferation. This study indicates that
LSPCs in favorable risk AML are regulated by extrinsic
signals such as BM-inﬁltrating CD8+ T cells, whereas
mainly cell-intrinsic mechanisms drive LSPC expansion
in aggressive AML.
Materials and methods
Patients
Blood and BM aspirates from patients diagnosed
with AML at the Department of Medical Oncology,
University Hospital Bern were prospectively collected.
Thirty patients were selected from this repository based
on the FACS immune-phenotype of the AML cells and
the risk category. The clinical and molecular character-
istics of the AML patients and controls are listed in
Supplementary Table 1. This study was approved by the
local ethical committee (Kantonale Ethikkommission
Bern, KEK122/14).
Molecular proﬁling and correlation network
modeling
Transcriptomic analysis was performed on 111 different
well-deﬁned FACS-puriﬁed samples of hematopoietic stem/
progenitors and paired CD8+ T cells from 30 AML patients
and 7 controls. Modeling of several tens of thousands of
predictive correlation network was assessed to map poten-
tial links between genes expressed in stem/progenitor cells
and paired CD8+ T cells in all AML patients of different
risk groups and controls. Selection of investigated genes,
biological signaling, and correlations were further func-
tionally validated. For details, see Supplementary Methods.
Data availability
All transcriptomic data compiled for this study have been
deposited in NCBI GEO under the accession code
GSE117090. In addition, expression data from GEO public
repository was assessed as a validation cohort (GSE6891).
Complete methods are included in the Supplementary
Appendix.
Results
A silenced gene expression pattern in CD8+ T cells
correlates with improved prognosis in AML
We ﬁrst characterized the complete gene expression signature
of FACS-puriﬁed CD34+CD38− AML LSCs, CD34+CD38+
AML progenitors and paired CD8+ T cells in the BM of
AML patients at the time point of diagnosis (Supplementary
Fig. 1, Supplementary Table 1). As expected, patients in the
favorable risk group had a better overall survival in com-
parison to the other AML risk groups (Supplementary
Fig. 2).
The expression of 258 genes was signiﬁcantly changed
in BM-inﬁltrating CD8+ T cells from AML patients com-
pared to healthy donors (Supplemental Dataset 1). Inter-
estingly, 222 genes were down-regulated and only 36 genes
were up-regulated (Fig. 1a, b). The down-regulated genes
are involved in signaling pathways related to T cell acti-
vation, differentiation, and function, such as NFkB, Wnt,
FoxO, T cell receptor (TCR), and cytokine/chemokine
signaling (Fig. 1c). The expression proﬁle of key genes for
T cell polarization in CD8+ T cells of AML patients
revealed a TC1 phenotype in controls but a skewing
towards a TC2 phenotype in AML patients (Fig. 1d). Out of
the 222 down-regulated genes, we deﬁned a 40-gene panel
of genes that belong to the NFkB, Wnt, FoxO and
Notch pathway, TCR and cytokine/chemokine signaling
according to the results of the gene ontology enrichment
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and pathway analysis (Fig. 1c, Supplementary Table 2).
Based on the calculated mean gene expression level of
these 40 pre-deﬁned genes, outcome-based cut-points
were deﬁned using X-Tile software [26]. AML patients
with a mean gene expression below or above the deﬁned
cut-point were classiﬁed as patients with a “silenced
gene expression (SGE) signature” or “non-silenced gene
expression” (non-SGE) signature, respectively. Principal
component analysis (PCA) revealed a closer similarity
between the non-SGE group and healthy controls while
patients with the SGE signature exhibited more distinct
gene expression patterns (Fig. 1e). Importantly, patients
with a SGE signature in BM CD8+ T cells had a sig-
niﬁcantly better overall survival compared to patients with a
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non-SGE signature (Fig. 1f). Although the analysis in the
different risk groups is limited by a rather small sample size,
the expression of a SGE signature correlated with longer
survival only in the favorable risk but not in the inter-
mediate or adverse risk group (Supplementary Fig. 3).
Multivariate analysis for the SGE signature adjusted for
AML risk group, patient age, percentage of blasts in BM
and blood, leukocyte counts, and sex, conﬁrmed the SGE
signature as an independent prognostic marker for overall
survival in our analyzed AML patient cohort (Fig. 1f).
To validate the prognostic value of this 40-genes panel in
a larger cohort of AML patients, we analyzed the expression
of these genes in a publically available dataset comprising
gene expression of non-fractionated BM cells of AML
patients [27, 28]. Our deﬁned 40-gene panel showed sig-
niﬁcantly better overall survival for patients with a SGE
signature than for patients with a non-SGE signature. Cox-
regression analysis further conﬁrmed the SGE signature as a
prognostic marker for overall survival (Fig. 1g).
In our analysis, we observed a systemic down-regulation
of genes in AML CD8+ T cells compared to controls.
Chromatin modiﬁcation mainly via histone deacetylation is
one of the key mechanisms for gene silencing [29]. Only
36 genes were up-regulated in AML CD8+ T cells (Fig. 1b).
Pathway enrichment analysis revealed that these 36 up-
regulated genes are primarily involved in the control of
chromatin organization or negative regulation of transcrip-
tion and gene expression (Fig. 1h). Nine of these 36 up-
regulated genes are controlling chromatin organization/
regulation (Fig. 1i). Chromosomal position-based gene-
mapping analysis (karyogram) showed that down-regulated
genes were not randomly distributed all over the genome
but signiﬁcantly enriched in some particular regions. These
data suggest altered histone organization in particular
chromosomal regions in leukemic CD8 T cells (Fig. 1j).
Histone deacetylation catalyzed by the histone deacety-
lase (HDAC) is a central switch of permissive to repressive
chromatin domains leading to transcriptional silencing [30].
To functionally test the effect of histone deacetylation on the
observed SGE signature, we treated FACS-puriﬁed CD8+
T cells isolated from three AML patients with SGE
signature and from two AML patients with non-SGE sig-
nature with the HDAC inhibitor, valproic acid (VPA). VPA
treatment signiﬁcantly reversed the SGE phenotype and
increased the expression of 10 selected key genes involved
in the regulation of Wnt-, Notch-, MAPK-signaling, T cell
differentiation, and in metabolism. In contrast, VPA did not
change the expression of these genes in T cells with non-
SGE signature (Fig. 1k). In addition, VPA treatment did not
change the expression of IL3 in CD8+ T cells from different
AML patients, indicating that IL3 gene expression in T cells
is not regulated by histone deacetylation (Fig. 1k).
Overall, these data indicate that important genes involved
in CD8+ T cell activation, differentiation, and function
are down-regulated in AML due to pathologic epigenetic
alterations mainly mediated via histone deacetylation.
Down-regulation of these genes in CD8+ T cells correlates
with an improved prognosis of AML patients.
LSPCs from AML patients display a dysregulated
expression of genes involved in proliferation,
stemness, and immune-recognition
We next investigated the gene expression signature of
CD34+CD38− AML LSCs and CD34+CD38+ AML pro-
genitors. HSPCs from healthy donors (Ctrl) had a similar
gene expression proﬁle and therefore clustered together in
the PCA. In contrast, the gene expression of AML cells was
more diverse and differed from healthy controls (Fig. 2a). In
AML LSCs and progenitors, 403 and 1309 genes were
differentially expressed compared to controls, respectively
(Fig. 2a, Supplementary Dataset 1). A comprehensive
pathway analysis of the differentially expressed genes
revealed that mainly pathways related to stemness, cell
proliferation, cell cycle, or immune cell signaling were
changed in AML LSCs and progenitor cells (Fig. 2b). The
Fig. 1 A silenced gene expression pattern in CD8+ T cells correlates
with improved prognosis. a Volcano plot showing differentially
expressed genes of leukemia CD8+ T cells (AML vs. Ctrl); y-axis:
negative log of P-value; x-axis: log2-fold change; red dots: up-
regulated genes; blue dots: down-regulated genes. b Heatmap illus-
trating differentially expressed genes in CD8+ T cells (AML vs. Ctrl).
c Pathway enrichment analysis of 222 down-regulated genes.
d Heatmap illustrating the expression proﬁle of key genes for CD8+ T
cell phenotype polarization. Silenced gene expression (SGE); non-
silenced gene expression (non-SGE). e PCA indicating the similarities
between CD8+ T cells with SGE or non-SGE signature and controls
according to their gene expression proﬁle. f Kaplan–Meier plots of
overall survival (OS) for AML patients according to the 40-gene panel
of CD8+ T cells. Multivariate analysis for SGE signature adjusted for
AML risk groups, age, percentage of blasts in BM and blood, leuko-
cyte counts, and sex. g Kaplan–Meier plots of overall survival (OS)
for AML patients in the validation cohort according to the 40-gene
signature of CD8+ T cells. Cox-regression analysis for SGE signature
in the validation cohort. h Pathway enrichment analysis of 36
up-regulated genes. i Heatmap illustrating the expression proﬁle of
up-regulated histone organizer/regulator genes. j Karyogram panel
shows signiﬁcant enrichment of down-regulated genes to particular
regions in the genome. Important selected genes are highlighted in
blue. k Expression proﬁle of selected genes from three AML patients
with SGE signature (AML #15, favorable group; AML #29, inter-
mediate group; AML #1, adverse group) and T cells from two AML
patients with non-SGE signature (AML #7, favorable group and AML
#28, adverse group). Analysis was performed immediately after
FACS-purifying (untreated) and after 24 h treatment with VPA or
vehicle. The fold differences of gene expression were calculated as the
ratio of treated (VPA or vehicle) vs. untreated conditions. Statistics:
f, g log-rank test; and multiple Cox-regression, k Student’s t-test
(2-tailed). *P < 0.05, **P < 0.01, ***P < 0.001. CI conﬁdence interval,
OS overall survival. (See also Supplementary Fig. 2–3; Supplementary
Table 2; Supplementary Dataset 1)
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number of 155 genes (58 up-regulated and 97 down-
regulated genes) were similarly dysregulated in AML LSCs
and progenitors when compared to controls (Fig. 2c).
Pathway enrichment analysis revealed that up-regulated
genes are mainly involved in cell proliferation, cell cycle, or
immune-related signaling while down-regulated genes
are primarily involved in signaling pathways mediating
antigen-presentation and interaction with immune cells
(Fig. 2c). Taken together, AML LSCs and progenitors had a
higher expression of genes involved in stemness and cell
proliferation compared to HSPCs whereas the down-
regulated genes and pathways facilitate immune-escape.
Fig. 2 Gene expression analysis of LSPCs from AML patients. a PCA
of AML LSPCs and control HSPCs. Volcano plots representing dif-
ferentially expressed genes of CD34+CD38− and CD34+CD38+ AML
and control cells; y-axis: negative log of P-value; x-axis: log2-fold
change; red dots: up-regulated genes; blue dots: down-regulated genes.
b Pathway enrichment analysis of differentially expressed genes in
each cell population. c Venn-diagram of signiﬁcant up/down-regulated
genes within leukemia stem/progenitor cells (AML vs. Ctrl). Heatmap
indicating the proﬁle of 155 differentially expressed intersection genes
(58 up-regulated and 97 down-regulated genes). Pathway enrichment
analysis of 58 up-regulated and 97 down-regulated intersection genes.
(See also Supplementary Dataset 1)
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Fig. 3 Gene expression signature of leukemia stem/progenitor cells
and paired CD8+ T cells across AML risk groups. a Venn-diagrams
showing differentially expressed genes in CD34+CD38− LSCs,
CD34+CD38+ progenitors and CD8+ T cells across AML risk groups
(favorable, intermediate, or adverse vs. Ctrl). b Pathway analysis of
differentially expressed genes in LSPCs and CD8+ T cells across AML
risk groups. c Gene set enrichment analysis (GSEA) representing the
normalized enrichment score (NES) of gene sets linked to Wnt
signaling for LSPCs and CD8+ T cells (favorable, intermediate,
or adverse vs. Ctrl). Bar charts showing the number of up-regulated
Wnt-related/target genes in AML patients from different risk cate-
gories vs. controls. Statistics: Student’s t-test (2-tailed). *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001. (See also Supplementary
Dataset 1)
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Genes involved in immunosurveillance are down-
regulated whereas stemness-related genes are up-
regulated in adverse risk AML
We next compared the gene expression proﬁles of AML
LSCs, progenitors, and paired CD8+ T cells between the
three different risk categories (Fig. 3a). AML progenitors
shared 294 dysregulated intersection genes across all AML
risk categories. In contrast, only 67 intersection genes were
found in AML LSCs. The gene expression proﬁle of BM
CD8+ T cells differed signiﬁcantly between the different
risk groups with only 39 intersection genes that were
similarly altered in all three-risk categories (Fig. 3a). AML
progenitors, which comprise the highly proliferative AML
cells, showed the highest expression of genes related to cell
cycling. In contrast, genes involved in stemness- and
leukemogenesis-related pathways were expressed at higher
levels in AML LSCs (e.g., Wnt, ErbB, and NF-kB). These
stemness-related pathways were expressed at highest levels
in LSCs from adverse risk AML and at lowest levels in
LSCs from the favorable risk group. This ﬁnding is in line
with previous studies indicating that a LSC-related gene
signature is a negative prognostic marker in AML [31, 32].
Furthermore, genes involved in immune-related pathways
such as cytokine–cytokine receptor interactions and cyto-
kine/chemokine signaling were more expressed in LSCs
from favorable risk AML but were not expressed in adverse
risk AML (Fig. 3b).
In line with these ﬁndings, genes involved in pathways
mediating immune cell function and target cell recognition
such as TCR and chemokine signaling as well as cytokine–
cytokine receptor interaction were more expressed in paired
CD8+ T cells from favorable risk AML but were down-
regulated in the adverse risk group. Similarly, signaling
pathways involved in T cell effector function, such as NF-
kB and Notch signaling, were signiﬁcantly down-regulated
in CD8+ T cells isolated from intermediate and adverse risk
AML patients [33]. The Wnt pathway, which is crucial for
the differentiation into memory T cells [33, 34], was inac-
tivated in CD8+ T cells from patients with adverse risk
AML (Fig. 3b). These results suggest that T cells in inter-
mediate and high risk AML are less functional than in
favorable risk AML and might be exhausted. However, the
analysis of markers deﬁning exhausted CD8+ T cells on
gene level did not reveal differences between the AML risk
groups (Supplementary Fig. 4). Importantly, the frequency
of BM-inﬁltrating CD8+ T cells did not differ between the
AML risk groups or healthy controls (Supplementary
Fig. 5). This indicates that functional but not numerical
differences lead to the CD8+ T cell-mediated expansion of
LSPCs in favorable risk AML.
Wnt signaling is fundamental for stemness and effector
function of LSCs and CD8+ T cells, respectively [12]. Gene
set enrichment analysis (GSEA) in our AML cohort
revealed a signiﬁcant enrichment for genes involved in Wnt
pathway activation in LSPCs from intermediate and adverse
risk group AML patients, but not in LSPCs from the
favorable risk group. In contrast, Wnt-related genes were
down-regulated in paired CD8+ T cells from AML patients
of the intermediate and adverse risk group (Fig. 3c). These
results suggest that LSPCs of adverse risk AML patients
develop and expand largely independently of CD8+ T cells,
whereas CD8+ T cells are mainly active in favorable risk
AML patients.
CD8+ T cells regulate LSPCs in favorable but not
adverse risk AML
To deﬁne possible interactions of genes/pathways in CD8+
T cells with genes/pathways in AML LSPCs, comprehensive
correlation networks were constructed. In each network, a
node was deﬁned as a gene expressed either in CD8+ T cells
or in LSPCs. A node (gene) in one cell that correlates sig-
niﬁcantly with more than 15 nodes in the other cell type was
considered as a hub (high-degree correlated node) (Fig. 4a).
The assumption was that a gene expressed in CD8+ T cells
communicates or coordinates other genes in LSPCs or vice
versa. Three types of correlations were detected: (1)
“appear”, a correlation present in AML but not in controls,
(2) “disappear”, a correlation present in the controls and
absent in AML, and (3) “ﬂip”, where the direction of the
correlation changes.
The highest number of nodes was detected in AML
progenitor cells and in CD8+ T cells, whereas few nodes
were detected in AML LSCs (Fig. 4a, b). Interestingly, the
highest number of hubs were detected in CD8+ T cells,
whereas fewer hubs were found in LSPCs (Fig. 4a, b,
Supplementary Dataset 2). We next analyzed these net-
works in the different AML risk categories (Fig. 4c, d). The
number of nodes in the “appear network” in AML LSPCs
and CD8+ T cells gradually decreased from the favorable
risk to the adverse risk group (Fig. 4d). In contrast, the
number of nodes in “disappear” and “ﬂip networks” did not
change across AML risk groups (Fig. 4c, d). Importantly,
the majority of hubs in CD8+ T cells were present in the
favorable risk group and their number gradually decreased
in the intermediate and adverse risk groups (Fig. 4e). No
CD8+ T cells hubs were detected in intermediate and
adverse risk groups that were not present in the favorable
risk group (Fig. 4e, f). Only few hubs were identiﬁed in
CD34+CD38+ progenitors. However, similar to CD8+
T cells, reduced number of hubs were identiﬁed with
increased risk category (Fig. 4e, Supplementary Fig. 6).
The majority of nodes within AML LSPCs, which were
connected to CD8+ hubs, were up-regulated compared to
controls (Supplementary Fig. 7). The number of nodes in
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LSPCs connected to given hubs in CD8+ T cells was gra-
dually decreased from favorable to intermediate and adverse
risk AML (Supplementary Table 3).
In order to identify the signaling pathways in AML
LSPCs, which are modulated by the identiﬁed CD8+ T cell
hubs, we performed a pathway analysis. The signiﬁcantly
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altered pathways in LSPCs included stemness, cell pro-
liferation and survival, immune-related signaling, gene
expression regulation, growth factor signaling, and meta-
bolism which were most activated in favorable risk AML
(Fig. 4g, Supplementary Fig. 7).
Taken together, our correlation network modeling indi-
cated that CD8+ T cells regulate LSPCs in favorable risk
AML. This interaction is reduced or absent in intermediate
and adverse risk AML.
CD8+ T cells induce the expansion and maintenance
of LSPCs in favorable risk AML
To functionally analyze the potential inﬂuence of CD8+
T cells on LSPCs, we FACS-puriﬁed both LSCs or AML
progenitor cells together with paired CD8+ T cells from BM
of nine different AML patients (Fig. 5a, Supplementary
Table 1). The co-culture of CD8+ T cells with LSCs
resulted in an up to 2-fold increase in colony-formation
compared to LSC mono-culture in the favorable risk group.
In contrast, the increase in colony formation in intermediate
and adverse risk was less pronounced and only observed at
higher T cell:LSC ratios (Fig. 5b). In addition, the number
of cells per colonies was not signiﬁcantly changed, sug-
gesting that differentiation was not affected by co-culture of
LSPCs with CD8+ T cells (Fig. 5c). Further re-plating of
cells derived from primary colony assays showed a sig-
niﬁcant difference in the colony-formation capacity of co-
cultured LSCs with a higher ratio of CD8+ T cells com-
pared to LSC mono-culture. This indicates that LSCs with
unimpaired self-renewal capacity are expanded by CD8+
T cells (Supplementary Fig. 8).
MGAT5 was identiﬁed as a hub in CD8+ T cells of all
risk groups. However, while MGAT5 positively correlated
with the expression of IL3 and other important genes
in CD34+CD38+ progenitors in favorable risk AML
patients, this correlation is lost in intermediate and adverse
risk AML (Fig. 5d, e, Supplementary Fig. 9, Supplementary
Dataset 2).
Our results suggest that CD8+ T cells regulate LSPCs in
favorable AML by inducing the production of important
hematopoietic cytokines such as IL-3. To address this
possibility, we co-cultured FACS-puriﬁed CD8+ T cells
with paired LSPCs derived from the same patients of
favorable risk AML and analyzed the expression of IL3
mRNA and protein. LSPCs of all risk groups expressed the
IL-3 receptor alpha (IL-3Ra). While, CD8+ T cells did not
express IL3Ra on mRNA and protein levels (Supplemen-
tary Fig. 10). Co-culture with CD8+ T cells resulted in an
up to 3-fold increase in IL3 mRNA expression in LSPCs
and an up to 2-fold increase in IL-3 protein expression in
culture supernatants compared to LSPCs mono-culture from
favorable risk AML (Fig. 5f). In healthy controls, the
expression of MGAT5 in CD8+ T cells did not correlate
with IL3 expression in progenitors (Supplementary
Fig. 11a). In addition, co-culture of CD8+ T cells with
CD34+ HSPCs derived from healthy donors did not
increase the level of IL3 mRNA expression (Supplementary
Fig. 11b). However, co-culture of pooled CD8+ T cells
derived from three good risk AML patients signiﬁcantly
increased the colony formation capacity of both, AML
LSCs and control HSCs (Supplementary Fig. 11c). Inter-
estingly, colony formation in LSCs was increased sig-
niﬁcantly more than in HSCs. This suggests that AML
LSCs have a higher proliferative capacity in response to
stimulation by CD8+ T cells than normal HSCs. Therefore,
favorable risk AML LSPCs respond to similar interactions
with CD8+ T cells as normal HSPCs. However, only BM-
inﬁltrating CD8+ T cells of AML patients but not of healthy
donors induce IL-3 production in LSCs and HSCs.
Knockdown of MGAT5 gene in CD8+ T cells using a
siRNA before initiation of the co-culture revealed an up to
2-fold decrease in IL3 mRNA expression in LSPCs
(Fig. 5g). The level of MGAT5 gene expression after siRNA
treatment of CD8 T cells signiﬁcantly correlated with the
IL3 expression in co-cultured LSPCs (Fig. 5h). In silico
pathway analysis predicted that MGAT5 expressed in CD8+
T cells triggers the expression of IL3 in LSPCs via EGF/
EGFR, IL-2 or IFNγ signaling (Supplementary Fig. 9a).
Correlation analysis conﬁrmed a signiﬁcant positive corre-
lation between IL3 expression in CD34+CD38+ progenitors
and EGF/EGFR or IL2 expression in CD8+ T cells in
favorable risk AML but not in intermediate or adverse risk
AML (Supplementary Fig. 9b–c). We tested this concept
experimentally by co-culturing FACS-puriﬁed CD34+
LSPCs with paired CD8+ T cells in the presence of neu-
tralizing antibodies to these speciﬁc cytokines and growth
factor receptor. Blocking EGFR and IL-2, but not IFNγ
reduced IL3 mRNA expression in FACS-puriﬁed CD34+
Fig. 4 Correlation network modeling between leukemia stem/pro-
genitor cells and paired CD8+ T cells. a Schematic view of correlation
networks for AML samples (“disease”). The red box represents hubs
with a high degree of correlations and black box indicates low degree
correlated nodes. b Quantiﬁcation of hub and node genes in LSPCs
and CD8+ T cells. c Schematic view of correlation networks that only
appear in one or more of the AML groups but not in the healthy
controls (“appear”); networks which are only detectable in control
samples but not in any of the AML risk groups (“disappear”); net-
works that are signiﬁcant in both the control group and patient groups
but have opposite signs (“ﬂip”). d Bar graph representing the number
of node gene in the appear, disappear, and ﬂip networks, in different
AML risk categories. e Quantiﬁcation of hub genes in the appear
network in AML risk categories. f Venn-diagram of CD8+ T cells’
hubs genes in different AML risk categories. g Pathway analysis of
node genes within LSPCs that show signiﬁcant correlation to CD8+ T
cell hubs. (See also Supplementary Fig. 6–7; Supplementary Table 3;
Supplementary Dataset 2)
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LSPCs (Fig. 5i). This ﬁnding indicates that CD8+ T cells
induce IL-3 production in LSPCs mainly by IL-2 and EGF/
EGFR signaling.
Neutralization of IL-3 in the co-culture of CD8+ T cells
with LSCs from favorable risk AML patients signiﬁcantly
decreased the colony-formation capacity (Fig. 5j). In
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addition, co-culture of CD34+ LSPCs with CD8+ T cells
resulted in the up-regulation of selected genes that are
regulated by hubs with documented function in hemato-
poiesis, leukemia development, cell proliferation, or
immune tolerance (CD47, CD58, CD63, CD99, and IL17b)
(Fig. 5k, Supplementary Table 3) [35–39].
Taken together, these ﬁndings indicated that BM CD8+
T cells induce pathways in favorable risk LSPCs that pro-
mote leukemia development, such as the autocrine pro-
duction of hematopoietic cytokines. In contrast, LSPCs in
more aggressive forms of AML develop largely indepen-
dent of CD8+ T cells (Fig. 5l).
Discussion
It is well documented that the immune system contributes to
the control of solid tumors, a process called “tumor
immunosurveillance”. However, cancer cells evade immune
recognition and elimination by cytotoxic CD8+ lympho-
cytes via various mechanisms, including loss of antigen and
the expression of immune inhibitory molecules [40, 41].
Thus, tumor-inﬁltrating lymphocytes (TILs) are often dys-
functional or “exhausted” due to the interaction with
immune inhibitory ligands expressed by tumor cells [40].
The presence of dysfunctional CD8+ T cells in TILs is a
negative prognostic and predictive factor for the response to
treatment with immune-checkpoint inhibitors [42, 43].
In the present study, we analyzed the gene expression
signature of BM CD8+ T cells together with paired AML
LSCs and progenitor cells. The majority of differentially
expressed genes were down-regulated in CD8+ T cells
derived from AML patients. The down-regulated genes are
involved in key functions of T cell activation and differ-
entiation including NFkB, Notch, Wnt, FoxO, TCR, and
cytokine/chemokine signaling. This indicates that similar to
TILs in solid tumors, CD8+ T cells in the AML BM are
dysfunctional. Surprisingly, patients with dysfunctional
CD8+ T cells as indicated by a SGE signature had a sig-
niﬁcantly better survival compared to patients with non-
SGE signature. This difference may be explained by the
fact that TILs comprise a population of activated tumor-
speciﬁc T cells whereas the BM is a secondary lymphoid
organ that contains mainly memory T cells with different
speciﬁcities [44].
The up-regulated genes in CD8+ T cells of AML patients
included main drivers of histone deacetylation and epige-
netic regulation, which correlated with the SGE signature in
our study population. HDAC enzymes regulate key func-
tions in T cells, such as maturation, migration, and TCR
signaling [45]. Recently, it was reported that the transcrip-
tion factors Tcf1 and Lef1 favor CD8+ T cell development
by HDAC mediated suppression of lineage-inappropriate
genes [46]. In addition, HDAC inhibitors enhance anti-
tumor activity of antigen-speciﬁc cytotoxic T cells against
solid tumors and multiple myeloma [47]. Similarly, treat-
ment of AML and myelodysplasia patients with azacitidine
and VPA induces a CD8+ T-cell response to the MAGE
cancer testis antigen [48]. This suggests that a SGE sig-
nature of T cells might be reversed by treatment with
demethylating agents.
To deﬁne possible interactions of CD8+ T cells with
human AML LSPCs, we performed a comprehensive cor-
relation network analysis. The goal of this analysis was to
identify genes in CD8+ T cells that regulate pathways in
LSPCs and vice versa (hubs). Interestingly, most hub genes
were identiﬁed in CD8+ T cells whereas only few hubs
were present in LSPCs. The number of CD8+ T cell hubs
was the highest in favorable risk AML and then gradually
lower from intermediate to adverse risk AML. In addition, a
given CD8+ T cell hub correlated with the highest number
of genes (nodes) in LSPCs from favorable risk group and
this number was gradually reduced in intermediate to
adverse risk AML. In addition, AML progenitors expressed
more node genes than AML LSCs, indicating that CD8+
T cells predominantly interact with progenitor cells. Our
ﬁnding suggests that CD8+ T cells regulate LSPCs in
favorable risk AML while more aggressive forms of AML
develop independently of BM-inﬁltrating CD8+ T cells.
Fig. 5 CD8+ T cells regulate LSPCs in favorable risk AML. a
Experimental setup. b, c Fold differences in the numbers of colonies or
cells from co-cultured conditions (LSCs with CD8+ T cells) vs. mono-
cultured (LSCs only) condition (three patients per each AML sub-
group; #3, #22, and #28 from adverse risk group; #5, #17, and #21
from intermediate risk group; #14, #15, and #26 from favorable risk
group). d An example of a correlation network in favorable group:
MGAT5 hub gene in CD8+ T cells is predicted as a coordinator for
different genes in LSPCs. e Correlation analysis of MGAT5 hub in
CD8+ T cells vs. IL3 in CD34+CD38+ cells in different AML risk
categories. f IL3 gene expression in re-puriﬁed LSPCs from mono-
culture or co-culture with CD8+ T cells; (three AML patients from
favorable risk category). IL-3 protein in culture supernatants of LSPCs
monocultures and co-cultures with CD8+ T cells. g MGAT5 and IL3
gene expression quantiﬁcation upon siRNA-mediated gene silencing
of MGAT5. The fold differences of gene expression were calculated as
the ratio of siMGAT5 treated condition vs. siCtrl in re-puriﬁed cell
populations (three AML patients from favorable risk category).
h Correlation analysis of MGAT5 expression in CD8+ T cells vs. IL3
in LSPCs after MGAT5 gene knockdown. i IL3 gene expression in
FACS-puriﬁed favorable risk AML CD34+ LSPCs from mono-culture
or co-culture with CD8+ T cells in the presence of neutralizing anti-
bodies to EGFR, IL-2, or IFNγ (n= 3; mean ± SD). j Fold differences
in the numbers of colonies from LSC monocultures- and co-cultures
with CD8+ T cells upon neutralization with αIL-3 antibody (three
patients from favorable risk AML). k Heatmap illustrating expression
proﬁle of ﬁve selected genes in re-puriﬁed LSPCs after mono-culture
or co-culture with CD8+ T cells (three AML patients from favorable
risk category). l Graphical scheme of the interaction between CD8+
T cells and LSPCs. Statistics: Student’s t-test (2-tailed). *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001. (See also Supplementary
Fig. 8–11; Supplementary Dataset 2)
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According to our comprehensive network modeling,
hubs in CD8+ T cells modulate stemness, cell-proliferation
and cell-survival, immune-related signaling, and growth
factor signaling mainly in favorable risk AML. CD8+
T cells’ hub genes in favorable risk AML, correlate with an
increased gene expression of cytokine/chemokines such as
IL3 and IL17B, and cell surface molecules (e.g., CD47,
CD58, CD63, and CD99) that have been associated with
hematopoiesis, leukemia development, cell proliferation, or
immune tolerance [35–39, 49].
Our results indicated that CD8+ T cells induce IL3
production in AML LSPCs via IL2 and EGF signaling
leading to their expansion. This is in agreement with reports
documenting that IL-3 increases proliferation and expansion
of CML stem cells and AML blasts [50, 51]. Interestingly,
the level of IL-3Ra expression on AML blasts is associated
with increased cellularity, enhanced proliferation, and with
poor prognosis [52].
CD8+ T cells regulate LSPCs mainly in favorable risk
AML, while more aggressive forms of AML develop
independently of BM-inﬁltrating CD8+ T cells. The fre-
quency of AML-speciﬁc T cells is rather low [53, 54].
Therefore, the majority of the analyzed CD8+ T cells in the
BM may be BM-resident memory CD8+ T cells that are not
leukemia-speciﬁc. We document that in adverse risk AML,
the positive correlation between IL2 or EGF expressed in
CD8+ T cells to IL3 in AML progenitors was lost (Sup-
plementary Fig. 9c). We did not detect differences in the
level of gene silencing in CD8+ T cells in different risk
categories (Fig. 1, Supplementary Dataset 1). In addition,
we also tested the expression of markers used to char-
acterize exhausted CD8+ T cells (CD244 (2B4), CD160,
TIGIT, HAVCR2, LAG3, PDCD1 (PD-1)). This analysis did
not reveal a preferential expression of exhaustion markers in
T cells of intermediate or adverse risk AML (Supplemen-
tary Fig. 4). In addition, genes involved in immune-related
pathways such as cytokine–cytokine receptor interactions
and cytokine/chemokine signaling were expressed in LSCs
from favorable risk AML but were not expressed in adverse
risk AML (Fig. 3b). Therefore, we suggest that the lack of
interaction between CD8+ T cells and LSPCs in inter-
mediate and adverse risk AML is not due to alterations in
T cells but due to molecular changes in LSPCs in inter-
mediate and high risk AML that render them independent in
regard of proliferation and expansion. AML LSCs and
progenitors in aggressive AML had a higher expression of
genes involved in stemness and cell proliferation (as an
intrinsic driver of leukemia) compared to LSPCs in favor-
able risk AML, whereas the down-regulated genes and
pathways facilitated immune-escape and immune-tolerance.
Stemness signatures in blasts are an important negative
prognostic marker [12, 24]. The canonical Wnt pathway,
which is central for HSC maintenance and development, is
constitutively active in myeloid leukemia and of crucial
importance for LSCs [24, 55, 56]. Fusion proteins such as
AML1-ETO, MLL-ENL, PLZF-RARα, and PML-RARα
induce Wnt signaling via activation of γ-catenin [57–59]. In
addition, activating mutations in FLT3 are associated with
high β-catenin levels and correlate with poor overall sur-
vival in AML patients [59, 60]. We document that
stemness-related pathways, especially the Wnt pathway,
were more active in adverse risk than in intermediate or
favorable risk AML.
AML is a very heterogeneous disease. It is therefore not
surprising that the interaction of CD8+ T cells with LSPCs
also varies in different molecular subtypes of AML. Inter-
estingly, although the prognostic risk groups still comprise a
molecular very heterogeneous group of diseases, we found a
clear difference in the regulation of LSPCs. Favorable risk
AML have less intrinsic molecular abnormalities that drive
proliferation and stemness. The disease development
depends on external cues from the niche, e.g., from CD8+
T cells. In contrast, more aggressive AML is propagated
mainly by cell-intrinsic mechanisms and develop indepen-
dent of immune cells.
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